- Drug Manufacturers - General
- Healthcare
-
5.83
EPS
-
55.71
P/E
-
174B
MARKET CAP
-
2.70%
DIV YIELD
Company Overview
ONE AMGEN CENTER DRIVE,THOUSAND OAKS CA 91320,(805)447-1000
CEO
Mr. Robert A. Bradway
Employess
26700
Sector
Healthcare
Industry
Drug Manufacturers - General
Website
https://www.amgen.com
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Next Earnings Date
Oct. 29, 2024
Ex Dividends date
Sep. 06, 2024
Dividend Date
Aug. 16, 2024
YTD Performance
9.22%
Fiscal Year End
12-31
IPO Date
1983-06-17
Growth Rates
| (avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
|---|---|---|---|---|
| Sales/Revenue | 4.20% | 3.49% | 3.50% | 7.09% |
| EPS | 6.41% | -0.22% | 0.43% | 3.12% |
| Equity | -11.89% | -13.00% | -12.83% | 70.23% |
| Cash | 11.14% | 9.52% | 20.43% | 43.45% |
| Return On Capital (ROIC) | 12.52% | 13.42% | 11.30% | 9.53% |
Debt
| year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Short Term Debt | 1,440 | 1,590 | 87 | 91 | 2,950 |
| Long Term Debt | 63,200 | 37,400 | 33,200 | 32,900 | 27,000 |
| LT Finance Leases | 691 | 539 | 525 | 306 | 388 |
| Shares Outstanding | 535 | 538 | 570 | 586 | 605 |
| Market Cap | 154,000 | 141,000 | 128,000 | 135,000 | 146,000 |
Price
News
Amgen Stock Slides on Lowered Guidance
1 monthAmgen (AMGN) shares tumbled 5% Wednesday after the drug developer lowered its full-year earnings guidance.
investopedia.com
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
1 monthOn Tuesday, Amgen Inc. AMGN reported mixed second-quarter results.
benzinga.com
Why Amgen Stock Is Down Today Despite Solid Q2 Results
1 monthThe pharmaceutical company's second-quarter numbers were roughly in line with expectations. Amgen's slight earnings miss, however, was enough to spark a sizeable sell-off.
fool.com
Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat
1 monthAmgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024.
zacks.com
Amgen's MariTide Weight Loss Potential: Stock Outlook
1 monthAmgen NASDAQ: AMGN is a biotechnology firm that has made its way into the weight loss treatment battle. The company's shares have performed relatively well in 2024, providing a total return of 16%, outpacing its sector and the market.
marketbeat.com
Amgen Inc. (AMGN) Q2 2024 Earnings Call Transcript
1 monthAmgen Inc. (NASDAQ:AMGN ) Q2 2024 Results Conference Call August 6, 2024 4:30 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Bob Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations Vikram Karnani - EVP & President, Global Commercial Operations & Medical Affairs (Rare Disease) Jay Bradner - EVP, Research and Development & Chief Scientific Officer Peter Griffith - EVP & CFO Conference Call Participants Yaron Werber - TD Cowen Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Markets Mike Yee - Jefferies Umer Raffat - Evercore ISI Jay Olson - Oppenheimer Mohit Bansal - Wells Fargo Gregory Renza - RBC Capital Markets Chris Raymond - Piper Sandler Carter Gould - Barclays Terence Flynn - Morgan Stanley Chris Schott - JPMorgan Kripa Devarakonda - Truist Securities James Shin - Deutsche Bank Gary Nachman - Raymond James Operator My name is Julianne, and I will be your conference facilitator today for Amgen's Second Quarter 2024 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise.
seekingalpha.com
Amgen (AMGN) Reports Q2 Earnings: What Key Metrics Have to Say
1 monthThe headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Amgen (AMGN) Q2 Earnings and Revenues Beat Estimates
1 monthAmgen (AMGN) came out with quarterly earnings of $4.97 per share, beating the Zacks Consensus Estimate of $4.93 per share. This compares to earnings of $5 per share a year ago.
zacks.com
Amgen CFO talks Q2 earnings, obesity drug, and growth
1 monthAmgen (AMGN) posted second quarter revenue of $8.4 billion, topping expectations of $8.34 billion. Sales rose by 20% in the quarter, however, the company noted that lower net selling prices partially offset a 26% growth in volume for products.
youtube.com
Amgen Is Redoubling Its Efforts To Take On Weight-Loss Kingpins Novo, Lilly
1 monthAmgen stock fell late Tuesday after the biotech reported lighter-than-expected second-quarter profits, though sales beat.
investors.com
Amgen second quarter profit dips, sales rise 20%
1 monthAmgen on Tuesday said its second-quarter profit slipped 1% as higher expenses offset a 20% increase in revenue driven by the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.
reuters.com
AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
1 monthTHOUSAND OAKS, Calif. , Aug. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter 2024.
prnewswire.com